pisco_log
banner

幽门螺杆菌耐药现状及治疗进展

周 成会, 朱 瑶

摘要


幽门螺杆菌(Helicobacterpylori,HP)感染是一个全球性的公共卫生问题,WHO已将HP列为I类致癌因子,严重威胁着人类的健康。因此根除HP感染临床意义重大。但因耐药菌株的出现,HP感染率依然处于高位(40%-90%),同时根除率降低(2010-2013年下降至71.03%)。因此,本文对近年来HP的耐药现状和治疗策略进展做一综述。

关键词


幽门螺杆菌,耐药,致癌因子,根除率

全文:

PDF

参考


[1]Calvet X,Ramirez Lazaro MJ,Lehours P.Diagnosis and epidemiology of Helicobacter pylori infection[J]. Helicobacter,2013 Sep;18 Suppl 1:5-11.

[2]Leja M, Grinberga I, Bilgilier C, et al. Review: Epidemiology of Helicobacter pylori infection. Helicobacter. 2019;24(Suppl. 1):e12635:1-5.[3]Han Ran,Lu Hong,Jiang Ming-Wan et al. Multicenter Study of Antibiotic Resistance Profile of H.pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chong qing,China[J]. Gastroenterology research and practice vol.2016,(2016): 8547686.doi:10.1155 /2016/8547686.

[4]Georgopoulos SD, Papastergiou V, Karatapanis S .Current options for the treatment of Helicobacter pylori[J].Expert opin pharmacother,2013,14(2):211-23.

[5]Wang B,Lv ZF,Wang H.Standard triple therapy for Helicobacter pylori infection in china.a mental-analysis[J].World Journal of Gastroenterolo gy,2014,20(40):14973-14985.


Refbacks

  • 当前没有refback。